Table 2 Anti-proliferative effects of TL-895 in MCL and DLBCL cell lines.

From: Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies

Cell line

GI50 (µM)

IC50 (µM)

Max response (GI %)

MCL

 GRANTA-519

NA

NA

50

 Jeko-1

NA

NA

42

 JVM-2

6.81

17.90

135

 Maver-1

27.50

NA

53

 Mino

5.58

14.00

88

 REC-1

4.26

13.00

83

ABC-DLBCL

 HBL-1

0.56

10.30

89

 OCI-Ly3

NA

NA

39

 SU-DHL-2-epst

NA

NA

2

 SU-DHL-8-epst

23.00

25.70

62

 TMD8

0.01

0.01

181

 U-2932

1.97

6.60

105

GCB-DLBCL

 DB

NA

NA

25

 DOHH-2

9.39

11.40

130

 HT

NA

NA

17

 HU-DHL-1-epst

20.80

24.90

73

 OCI-Ly18

18.60

22.30

68

 OCI-Ly19

NA

NA

36

 Pfeiffer

19.60

21.00

99

 SU-DHL-4-epst

10.60

11.90

94

 SU-DHL-5-epst

NA

NA

42

 Toledo

3.84

5.18

195

  1. ABC-DLBCL activated B-cell like diffuse large B-cell lymphoma, IC50 half maximal inhibitory concentration, GCB-DLBCL germinal B-cell like subtype-diffuse large B-cell lymphoma, GI growth inhibition, GI50 50% growth inhibition, MCL mantle cell lymphoma, NA not available. NA, GI50 and IC50 values were not available as TL-895 did not reach growth inhibition levels > 50%. GI of 0% represents no growth inhibition, a GI of 100% represents complete growth inhibition (cytostasis) and a GI of 200% represents complete death (cytotoxicity) of all cells in the culture well.
Back to article page